November 17, 2009
November 2009 Pompe Program Update from Genzyme
Genzyme would like to provide an update to the US Pompe community about the status of the application for Lumizyme™
October 1, 2009
Amicus Therapeutics Announces Plan to Initiate Phase 1 Study of AT2220 for Pompe Disease
CRANBURY, N.J., Sept 30, 2009 – – Amicus Therapeutics today announced it plans to initiate a Phase 1 study of
July 23, 2009
Genzyme’s Second Quarter Earnings Statement
In their second quarter earning statement, Genzyme provided an update on the situation at the Allston manufacturing plant, and the
CAMBRIDGE, Mass. – Genzyme Corporation (Nasdaq: GENZ) announced today that it has submitted the final documentation to address all items
Dear IPA Affiliate, You will no doubt have heard the wonderful news that Myozyme from the Belgian production facility has